Bristol Myers Squibb (CELG-RI) Enterprise Value (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Enterprise Value of -$11.1 billion for Q2 2026, up 18.32% year-over-year from -$9.4 billion in Q2 2025, and down 5.88% quarter-over-quarter from -$10.5 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Enterprise Value (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Enterprise Value for 18 consecutive years, with -$11.1 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Enterprise Value rose 18.32% year-over-year to -$11.1 billion; the TTM figure through Jun 2026 stood at -$11.1 billion (up 18.32% YoY), while the FY2025 annual figure was -$10.6 billion, up 1.54% from the prior year.
- Enterprise Value eased to -$11.1 billion in Q2 2026 per CELG-RI's latest filing, from -$10.5 billion in the prior quarter.
- Across five years, Enterprise Value topped out at -$6.6 billion in Q2 2024 and bottomed at -$16.5 billion in Q3 2025.
- Historically, Enterprise Value has averaged -$10.7 billion across 5 years, with a median of -$10.5 billion in 2025.
- Annual changes were most pronounced in 2022 — Enterprise Value soared 45.61% — and 2025, when it sank 105.32%.
- Bristol Myers Squibb's Enterprise Value stood at -$9.2 billion in 2022, then tumbled by 32.94% to -$12.2 billion in 2023, then rose by 11.61% to -$10.8 billion in 2024, then climbed by 1.54% to -$10.6 billion in 2025, then slipped by 4.01% to -$11.1 billion in 2026.
- Business Quant data shows CELG-RI's Enterprise Value at -$11.1 billion in Q2 2026, -$10.5 billion in Q1 2026, and -$10.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.49 Bn | 632.73 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 470.91 Bn | 464.34 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 379.63 Bn | 372.49 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 303.14 Bn | 295.45 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 258.40 Bn | 253.50 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 237.10 Bn | 223.11 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 183.02 Bn | 179.84 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 161.60 Bn | 149.90 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 105.86 Bn | 101.70 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | -11.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.07 Bn |
| Mar 31, 2026 | -10.45 Bn |
| Dec 31, 2025 | -10.64 Bn |
| Sep 30, 2025 | -16.45 Bn |
| Jun 30, 2025 | -13.55 Bn |
| Mar 31, 2025 | -11.72 Bn |
| Dec 31, 2024 | -10.81 Bn |
| Sep 30, 2024 | -8.04 Bn |
| Jun 30, 2024 | -6.60 Bn |
| Mar 31, 2024 | -9.61 Bn |
| Dec 31, 2023 | -12.23 Bn |
| Sep 30, 2023 | -7.62 Bn |
| Jun 30, 2023 | -8.67 Bn |
| Mar 31, 2023 | -9.21 Bn |
| Dec 31, 2022 | -9.20 Bn |
| Sep 30, 2022 | -8.96 Bn |
| Jun 30, 2022 | -13.17 Bn |
| Mar 31, 2022 | -14.90 Bn |
| Dec 31, 2021 | -16.91 Bn |
| Sep 30, 2021 | -15.59 Bn |